HC Wainwright Predicts Lower Earnings for Moleculin Biotech

Moleculin Biotech, Inc. (NASDAQ:MBRX) – HC Wainwright lowered their FY2025 EPS estimates for Moleculin Biotech in a note issued to investors on Thursday, December 11th. HC Wainwright analyst S. Nik now anticipates that the company will post earnings per share of ($31.44) for the year, down from their prior forecast of ($21.25). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share. HC Wainwright also issued estimates for Moleculin Biotech’s Q4 2025 earnings at ($12.69) EPS and FY2026 earnings at ($9.99) EPS.

A number of other brokerages have also issued reports on MBRX. Roth Capital reissued a “buy” rating on shares of Moleculin Biotech in a report on Monday. Wall Street Zen downgraded Moleculin Biotech to a “strong sell” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Moleculin Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.00.

Moleculin Biotech Trading Down 9.6%

Shares of NASDAQ MBRX opened at $4.50 on Monday. The company has a market cap of $9.18 million, a price-to-earnings ratio of -0.14 and a beta of 1.58. Moleculin Biotech has a 12-month low of $4.42 and a 12-month high of $91.25. The stock’s 50 day simple moving average is $10.22 and its 200 day simple moving average is $12.39.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.07.

Hedge Funds Weigh In On Moleculin Biotech

A hedge fund recently raised its stake in Moleculin Biotech stock. Armistice Capital LLC boosted its holdings in Moleculin Biotech, Inc. (NASDAQ:MBRX) by 293.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,250,000 shares of the company’s stock after buying an additional 932,414 shares during the period. Armistice Capital LLC owned approximately 8.93% of Moleculin Biotech worth $1,217,000 as of its most recent SEC filing. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.